Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgRs on human dendritic cells

Journal of Immunotherapy

Volumn 31, Issue 2, 2008, Pages 113-120

  Banerjee, Devi ^a   Matthews, Phillip ^a   Matayeva, Elyana ^a   Kaufman, Jacob L ^a   Steinman, Ralph M ^a   Dhodapkar, Kavita M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Dendritic cells; Epidermal growth factor receptor; Fcg receptor; Glioma; Immunity; Monoclonal antibodies

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RANTES; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; CHEMOKINE; CYTOKINE; FCGR2B PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; GENE OVEREXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTERFERON PRODUCTION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; COCULTURE; DRUG EFFECT; GLIOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHEMOKINES; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY;

EID: 44949146272     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31815a5892     Document Type: Article

References (32)

1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
2. Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60:1383-1387.
3. Liu TF, Tatter SB, Willingham MC, et al. Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther. 2003;2:783-787.
4. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93: 1246-1256.
5. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother. 2003;52:342-346.
6. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-1157.
7. Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med. 2005;353: 1997-1999.
8. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
9. Eller JL, Longo SL, Kyle MM, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery. 2005;56:155-162; discussion 162.
10. Eller JL, Longo SL, Hicklin DJ, et al. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery. 2002;51:1005-1013; discussion 1004-1013.
11. Dhodapkar KM, Dhodapkar MV. Recruiting dendritic cells to improve antibody therapy of cancer. Proc Natl Acad Sci USA. 2005;102:6243-6244.
12. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptormediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189: 371-380.
13. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med. 2002;195:F1-F3.
14. den Haan JM, Bevan MJ. Constitutive versus activation dependent cross presentation of immune complexes by CD8+ and CD8- dendritic cells in vivo. J Exp Med. 2002;196:817-827.
15. Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002;195:125-133.
16. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275-290.
17. Dhodapkar KM, Kaufman JL, Ehlers M, et al. Selective blockade of inhibitory Fc gamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibodycoated tumor cells. Proc Natl Acad Sci USA. 2005;102:2910-2915.
18. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fc receptors on dendritic cells. J Exp Med. 2002;195:1653-1659.
19. Dhodapkar KM, Banerjee D, Connolly J, et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007;204:1359-1369.
20. Banerjee D, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after DC injection of cytokine matured DCs in myeloma patients. Blood. 2006;108:2655-2661.
21. Tang J, Flomenberg P, Harshyne L, et al. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res. 2005;11:5292-5299.
22. Brooks WH, Markesbery WR, Gupta GD, et al. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol. 1978;4:219-224.
23. Fecci PE, Mitchell DA, Archer GE, et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003;64:161-176.
24. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515-5525.
25. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973-4979.
26. Parajuli P, Mathupala S, Mittal S, et al. Dendritic cell-based active specific immunotherapy for malignant glioma. Expert Opin Biol Ther. 2007;7:439-448.
27. de Vleeschouwer S, Rapp M, Sorg RV, et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery. 2006;59:988-999; discussion 999-1000.
28. Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 antiepidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-4328.
29. Okano F, Storkus WJ, Chambers WH, et al. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002;8:2851-2855.
30. Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96:1293-1301.
31. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006;12:4294-4305.
32. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294-3302.